SUPPLEMENTARY TABLE

Supplementary Table 1. The relationship between TACC3 overexpression and patient prognosis (Overall Survival) in different cancers.

Tumor types	TACC3 Overexpression	p-value
ACC	-	0.25
BLCA	+	0.55
BRCA	+	0.25
CESC	+	0.41
CHOL	-	0.12
COAD	+	0.15
DLBC	+	0.17
ESCA	-	0.39
GBM	+	0.36
HNSC	+	0.52
KICH	-	0.09
KIRC	+	**0.00003***
KIRP	-	0.0019**
LAML	-	0.0094**
LGG	-	0.00000000078***
LIHC	+	**0.0028**
LUAD	-	0.0001**
LUSC	+	0.36
MESO	-	0.00003***
OV	+	0.65
PAAD	+	0.27
PCPG	-	0.36
PRAD	-	0.11
READ	+	0.86
SARC	-	0.71
SKCM	+	0.52
STAD	+	0.24
TGCT	-	0.93
THCA	-	0.77
THYM	+	**0.013***
UCEC	+	0.96
UCS	+	0.089
UVM	-	0.13

The extension of these abbreviations was shown below; − means TACC not overexpression, + means TACC overexpression; P values mean patient overall survival between low and high TACC3. *$p<0.05$, **$p<0.01$, ***$p<0.001$.

Notes:

Tumor types:

ACC   Adrenocortical carcinoma
BLCA Bladder Urothelial Carcinoma
BRCA Breast invasive carcinoma
CESC Cervical squamous cell carcinoma and endocervical adenocarcinoma
CHOL Cholangio carcinoma
COAD Colon adenocarcinoma
DLBC Lymphoid Neoplasm Diffuse Large B-cell Lymphoma
ESCA Esophageal carcinoma
GBM   Glioblastoma multiforme
HNSC Head and Neck squamous cell carcinoma
KICH Kidney Chromophobe
KIRC Kidney renal clear cell carcinoma
KIRP Kidney renal papillary cell carcinoma
LAML Acute Myeloid Leukemia
LGG   Brain Lower Grade Glioma
LIHC Liver hepatocellular carcinoma
LUAD Lung adenocarcinoma
LUSC Lung squamous cell carcinoma
MESO Mesothelioma
OV   Ovarian serous cystadenocarcinoma
PAAD Pancreatic adenocarcinoma
PCPG Pheochromocytoma and Paraganglioma
PRAD Prostate adenocarcinoma
READ Rectum adenocarcinoma
SARC Sarcoma
SKCM Skin Cutaneous Melanoma
STAD Stomach adenocarcinoma
TGCT Testicular Germ Cell Tumors
THCA Thyroid carcinoma
THYM Thymoma
UCEC Uterine Corpus Endometrial Carcinoma
UCS   Uterine Carcinosarcoma
UVM   Uveal Melanoma